Pcn104 - Economic Analysis of Costs and Resource Consumption of Ixazomib in Patients With Relapsed / Refractory Multiple Myeloma in Austria

Value in Health - United Kingdom
doi 10.1016/j.jval.2018.09.187
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Phase 2 Trial of Ixazomib in Patients With Relapsed Multiple Myeloma Not Refractory to Bortezomib

Blood Cancer Journal
OncologyHematology
2015English

Phase I/Ii Trial of Bendamustine, Ixazomib, and Dexamethasone in Relapsed/Refractory Multiple Myeloma

Blood Cancer Journal
OncologyHematology
2019English

Ixazomib in the Treatment of Relapsed Multiple Myeloma

Medical Council
2018English

Bendamustine in Patients With Relapsed or Refractory Multiple Myeloma

European Journal of Medical Research
Medicine
2010English

Pcn73 - Budget Impact of Ixazomib in Combination With Lenalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma in Russia

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Arsenic Trioxide-Based Therapy in Relapsed/Refractory Multiple Myeloma Patients: A Meta-Analysis and Systematic Review

OncoTargets and Therapy
OncologyPharmacology
2014English

Carfilzomib for Relapsed or Refractory Multiple Myeloma

The Lancet Oncology
Oncology
2018English

Efficacy and Safety of Long-Term Treatment With Lenalidomide and Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma

Blood Cancer Journal
OncologyHematology
2014English

Low-Dose Lenalidomide and Dexamethasone Combination Treatment in Elderly Patients With Relapsed and Refractory Multiple Myeloma

Hematology
Hematology
2016English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy